MedTrace Logo

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

NCT02508805 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-05-09

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy and safety of Neuromultivit (solution for injections) in treatment of vertebrogenic radiculopathy L5, S1 in comparison with standard therapy. The patients are randomised into two groups: standard therapy group and standard therapy plus Neuromultivit group.

Conditions

  • Vertebrogenic Radiculopathy L5, S1

Interventions

DRUG

Neuromultivit

DRUG

Voltaren

DRUG

Sirdalud

Sponsors & Collaborators

  • Valeant Russia, LLC

    collaborator UNKNOWN

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Farit Khabirov, MD, DSc, Prof · State Autonomous Institution Republican Clinical Centre of Neurology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-09-30
Completion
2015-11-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02508805 on ClinicalTrials.gov